Ignite Creation Date:
2025-12-24 @ 10:32 PM
Ignite Modification Date:
2025-12-28 @ 2:10 PM
Study NCT ID:
NCT01292135
Status:
COMPLETED
Last Update Posted:
2014-07-24
First Post:
2011-02-02
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Sponsor:
Pharmacyclics LLC.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
PCYC-1108-CA
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None